Can Benfotiamine Help Alzheimer’s Disease? This is what scientists are trying to determine. According to Alzheimer's News Today, a large clinical trial has received $45 million in U.S. funding to evaluate the efficacy of benfotiamine — a lab-made precursor of thiamine or vitamin B1 — in slowing the cognitive decline of those with mild Alzheimer’s disease or mild cognitive impairment.
The grant was awarded to the National Institute of Health (NIH) to research the Burk Neurological Institute (BNI) in White Plains, New York. The lead researcher is Gary E. Gibson, Ph.D. at BNI/Weill Cornell Medicine.
But let's be clear, this is just a clinical trial! However, the goal is to expand early data from a pilot phase 2 study regarding the potential of Benfotiamine taken twice a day to slow the cognitive decline.
Simply put, the initial data showed that benfotiamine was safe and that cognitive decline was lower in patients treated with benfotiamine compared to those who received a placebo.
What do we need to know?
- Diabetes or pre-diabetes is the second biggest RISK factor for Alzheimer’s disease
- Diabetics are 65% more likely to develop Alzheimer’s disease than non-diabetics.
Researchers are referring to Alzheimer’s disease as “Type 3 diabetes” and the primary RISK for developing Type 3 diabetes is having Type 2 diabetes.
Are YOU at RISK?
It is still the early days of the research, however, the fact that there is such HUGE importance being put on the research indicates the possible benefits. Those who are impacted by any of the following should keep an eye on this study:
- Have a family history of diabetes
- Are you over 45 years of age
- Have high blood pressure (hypertension)
- Have excess body weight or obesity
- Has suffered from polycystic ovarian syndrome (PCOS)
- Has low physical activity
Prevention is worth a pound of cure! A little precaution before a crisis occurs is preferable to a lot of fixing up afterward. (Thank you, Ben Franklin!)
Free free to reach out more about the studies here:
- https://alzheimersnewstoday.com/news/45m-grant-funds-trial-benfotiamine-vitamin-b1-precursor-cognitive-decline/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769828/
- https://ucsdnews.ucsd.edu/pressrelease/novel-treatment-approach-to-alzheimers-disease-uses-vitamin-b1-derivative
- https://medicaldialogues.in/neurology-neurosurgery/news/use-of-vitamin-b1-derivativenovel-treatment-approach-to-alzheimers-disease-96362?infinitescroll=1
Disclaimer: The information included at this site is for educational purposes only and is not intended to be a substitute for medical treatment by a healthcare professional. Because of unique individual needs, the reader should consult their physician to determine the appropriateness of the information for the reader’s situation.
BenfoComplete is a business based on the goal of living a better life. We aim tirelessly to spread the good news about the amazing effects of nutraceutical Benfotiamine.
Because Benfotiamine is a dietary supplement, the FDA only requires manufacturers and distributors to have credible evidence as to its safety. The FDA itself has not evaluated Benfotiamine for safety or effectiveness. Benfotiamine therefore cannot be represented to diagnose, treat, cure, or prevent any disease. For more information on this and related topics, please review our FAQs on Benfotiamine for more information. THE STATEMENTS MADE BY BENFOCOMPLETE HAVE NOT BEEN EVALUATED BY THE FDA (U.S. FOOD & DRUG ADMINISTRATION). OUR PRODUCTS ARE NOT INTENDED TO DIAGNOSE, CURE OR PREVENT ANY DISEASE. BENFOTIAMINE.NET, INC. IS NOT AFFILIATED WITH ANY OF THE STUDIES MENTIONED ON THE WEBSITE. THE TESTIMONIALS ON THIS WEBSITE ARE INDIVIDUAL CASES AND DO NOT GUARANTEE THAT YOU WILL GET THE SAME RESULTS.
